Stephen Bailey

Why we cut our AstraZeneca holding

Stephen Bailey

Stephen Bailey, co-manager on the Liontrust Macro Equity Income fund comments on pharmaceuticals giant AstraZeneca following news that the “Mystic” study - its flagship research into lung cancer treatment - has failed.

This time last year we held over 5 per cent in AstraZeneca, but today that stands at 0.8 per cent – a reduction of around 85 per cent. We’re not negative on global healthcare as a theme – in fact we’re so positive on the sector’s unique macro-thematic backdrop and the associated tailwinds to earnings, dividends and valuations that it makes up about 15 per cent of the Liontrust Macro Equity Income fund. Rather, as we moved into 2017 we felt it prudent to reduce the potential for drug pipeline failure and capital risk. We were prompted by drug trial failures from US pharma giant Bristol-Myers Squibb, a company which shows striking similarities to AstraZeneca in terms of its industry leadership and – as it has transpired – misplaced prioritisation of immuno-oncology research. The failure of Bristol-Myers Squibb’s CheckMate drug trial led to a correction in excess of 20 per cent for the share price.

As we wrote back in February, the impact of Mystic on AstraZeneca’s share price was always going to be explicitly binary. Since January we’ve seen the company’s share price rise from around £45 to near £55 – much of this on the expectation of a positive result to Mystic. As the adage goes – “it’s better to travel than to arrive”. With the stock priced for success, we felt a disappointment would be a big shock, and saw the need to do something in advance of the outcome. Rumours abound on AstraZeneca’s M&A prospects – price wise it looks far more appealing as a target today than it did yesterday, but its prospects have diminished.

We much prefer GlaxoSmithKline, the largest holding in the fund, and its emphasis on long duration vaccine and consumer health assets, giving a reassuring visibility that is often lacked by more exciting peers.


• This content contains information and analysis that is believed to be accurate at the date of publication but is subject to change without notice. Whilst care has been taken in compiling this content, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness. Some parts/sections of this content may been compiled from external sources. Whilst these sources are believed to be reliable, the information has not been independently verified and therefore no representation is made as to its accuracy or completeness. • It should not be copied, faxed, reproduced, divulged or distributed, in whole or in part, without the express written consent of Liontrust. • Past performance is not a guide to future performance. Do remember that the value of an investment and the income generated from them can fall as well as rise and is not guaranteed, therefore, you may not get back the amount originally invested and potentially risk total loss of capital. The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term. • Any decision to invest should be always based on the final Prospectus and Key Investor Information Documents (KIIDs) and you should take independent legal advice if necessary. These documents contain important information which should be read before investing in any fund and they can be obtained, free of charge, here.

• Investment in Funds managed by the Macro Thematic team involves foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. The Funds' expenses are charged to capital. This has the effect of increasing dividends while constraining capital appreciation. The performance of the Liontrust GF Macro Equity Income Fund may differ from the performance of the Liontrust Macro Equity Income Fund and is likely to be lower than its corresponding Master Fund due to additional fees and expenses.

Friday, July 28, 2017, 2:50 PM